Clinical utility of azilsartan–chlorthalidone fixed combination in the management of hypertension
Jerrica E Shuster,1,2 Barry E Bleske,1,2 Michael P Dorsch1,21University of Michigan Hospitals and Health Centers, Ann Arbor, MI, USA; 2College of Pharmacy, University of Michigan, Ann Arbor, MI, USAAbstract: Azilsartan–chlorthalidone fixed combination is a new drug in the management of...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2012-06-01
|
| Series: | Vascular Health and Risk Management |
| Online Access: | http://www.dovepress.com/clinical-utility-of-azilsartanndashchlorthalidone-fixed-combination-in-a10094 |
| Summary: | Jerrica E Shuster,1,2 Barry E Bleske,1,2 Michael P Dorsch1,21University of Michigan Hospitals and Health Centers, Ann Arbor, MI, USA; 2College of Pharmacy, University of Michigan, Ann Arbor, MI, USAAbstract: Azilsartan–chlorthalidone fixed combination is a new drug in the management of hypertension. Azilsartan has been shown to have greater blood pressure-lowering effects than other angiotensin-receptor blockers (ARBs), and the debate regarding the superiority of chlorthalidone over hydrochlorothiazide has been ongoing for years. The combination is unique because it is the first to partner an ARB with this, possibly more effective, diuretic. This review will address trials involving both components of this drug, as well as phase III trials involving the fixed-combination product. The article will also discuss the benefit of combination therapy in the treatment of hypertension.Keywords: azilsartan, chlorthalidone, combination, hypertension |
|---|---|
| ISSN: | 1176-6344 1178-2048 |